Cellectis (CLLS) Change in Receivables (2015 - 2026)
Cellectis' (CLLS) quarterly Change in Receivables came in at $7.9 million in Q1 2026, up 3550.0% year-on-year from $217397.3 in Q1 2025, and up 116.45% quarter-over-quarter from $3.7 million in Q3 2025.
Cellectis (CLLS) Change in Receivables (2015 - 2026) Analysis & Trends
Cellectis' Change in Receivables history runs 12 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- On a quarterly basis, Change in Receivables rose 3550.0% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $9.5 million, a 85.59% decrease from a year earlier, with the FY2024 full-year figure at $52.6 million, up 2235.52% from the prior year.
- Change in Receivables grew to $7.9 million in Q1 2026 per CLLS's latest filing, from $3.7 million in the prior quarter.
- Across five years, Change in Receivables topped out at $61.4 million in Q2 2024 and bottomed at -$13.5 million in Q1 2024.
- The 5-year median for Change in Receivables is $171500.0 (2022), against an average of $3.8 million.
- Across the five-year window, Change in Receivables slumped 3769.7% in 2023 and surged 3550.0% in 2026, its largest moves.
- Year by year, Change in Receivables stood at $578000.0 in 2022, then soared by 203.29% to $1.8 million in 2023, then surged by 144.78% to $4.3 million in 2024, then slipped by 14.57% to $3.7 million in 2025, then soared by 116.45% to $7.9 million in 2026.
- Per Business Quant, the three latest CLLS Change in Receivables figures stand at $7.9 million (Q1 2026), $3.7 million (Q3 2025), and -$1.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | 7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.94 Mn |
| Mar 31, 2026 | 7.94 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -230,000.00 |
| Mar 31, 2025 | -230,000.00 |
| Dec 31, 2024 | 4.29 Mn |
| Dec 31, 2024 | 4.29 Mn |
| Sep 30, 2024 | 376,000.00 |
| Sep 30, 2024 | 376,000.00 |
| Jun 30, 2024 | 61.39 Mn |
| Jun 30, 2024 | 61.39 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | -497,000.00 |
| Sep 30, 2023 | -497,000.00 |